- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 111,20 | -0,04 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Tubulis GmbH, Planegg-Martinsried | Datum der Anmeldung:19.04.2026Aktenzeichen:B3-57/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Tubulis GmbH, Planegg-MartinsriedProduktmärkte:Antikörper-Wirkstoff-Konjugate... ► Artikel lesen | |
| ZOETIS | 99,52 | -0,20 % | Dividendenbekanntmachungen (20.04.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECCO GROUP AG CH0012138605 1 CHF 1,0875 EUR ANIMA HOLDING SPA IT0004998065 - 0,5 EUR BANCA MEDIOLANUM SPA IT0004776628 - 0,65... ► Artikel lesen | |
| INCYTE | 80,96 | +0,20 % | Incyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) | Daten aus der zulassungsrelevanten frontMIND-Studie zu Tafasitamab (Monjuvi/Minjuvi) bei der Erstlinienbehandlung des diffusen großzelligen B-Zell-Lymphoms (DLBCL) wurden im Rahmen eines Vortrags... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,376 | -0,15 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| AMARIN | 12,200 | -1,61 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,400 | -1,16 % | Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization | ||
| LIGAND PHARMACEUTICALS | 196,00 | -1,01 % | Ligand Pharmaceuticals: Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 | ||
| MADRIGAL PHARMACEUTICALS | 444,70 | +1,65 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 | ||
| ANI PHARMACEUTICALS | 66,50 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity | PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets... ► Artikel lesen | |
| TALPHERA | 0,680 | +3,03 % | Talphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million
All... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 25,330 | -2,09 % | Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors | ||
| SAVARA | 4,339 | 0,00 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,226 | 0,00 % | XFRA 5MP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIODEXA PHARMA ADR... ► Artikel lesen | |
| ARTIVION | 31,600 | -2,47 % | Artivion, Inc.: Artivion Announces U.S. FDA Approval of the NEXUS Aortic Arch System | Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections
ATLANTA, April 7... ► Artikel lesen | |
| HERON THERAPEUTICS | 1,006 | 0,00 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results | - ZYNRELEF- and APONVIE- Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise- Achieved $154.9 Million in 2025 Net Revenue- Issues Full-Year 2026 Net Revenue Guidance of $173 to $183... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.